Wockhardt Limited

WOCKPHARMA

INE049B01025

Pharmaceuticals

Market Closed - NSE India S.E. Other stock markets 12:40:00 18/05/2024 pm IST			5-day change	1st Jan Change
543.4 ^INR	+0.38%		+2.31%	+28.04%

03/04	Wockhardt Limited Announces Cessation of Independent Directors	CI
14/02	Wockhardt Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	CI

Wockhardt Limited Announces Appointment of Zahabiya Khorakiwala as Additional Director

October 30, 2017 at 01:17 pm IST

Wockhardt Limited announced, at board meeting held on October 30, 2017, the appointment of Zahabiya Khorakiwala as additional director (non-executive). Effective from October 30, 2017.

Latest news about Wockhardt Limited

Wockhardt Limited Announces Cessation of Independent Directors	03/04	CI
Wockhardt Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	14/02	CI
Wockhardt Limited Announces Successful Completion of Pivotal Phase 3 Pneumonia Study of Its Macrolide Antibody Nafithromycin WCK 4873	11/12	CI
Wockhardt Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	14/11	CI
CARE Cuts Rating on Wockhardt's Working Capital to BB+; Outlook Negative	06/23/06	MT
Wockhardt Limited Reports Earnings Results for the First Quarter Ended June 30, 2023	14/23/14	CI
Wockhardt Limited Announces Executive Changes	14/23/14	CI
CARE Keeps BBB- Rating on Wockhardt's Bank Financing	07/23/07	MT
Wockhardt Trims Consolidated Loss in Fiscal Q4	29/23/29	MT
Wockhardt Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2023	26/23/26	CI
INDIA STOCKS-Indian shares fall on rate-hike worries ahead of Fed, RBI minutes	22/23/22	RE
Wockhardt Widens Consolidated Net Profit in Fiscal Q3	14/23/14	MT
Wockhardt Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2022	13/23/13	CI
Wockhardt Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2022	04/22/04	CI
CARE Keeps Rating on Wockhardt's Long-term Bank Financing, Bonds; Outlook Stable	05/22/05	MT
Wockhardt Starts Global Phase 3 Clinical Study of Novel Antibiotic WCK 5222	16/22/16	MT
Wockhardt Announces Successful Initiation of Global Phase 3 Clinical Study of Its Novel Antibiotic WCK 5222	16/22/16	CI
Wockhardt Limited Reports Earnings Results for the First Quarter Ended June 30, 2022	12/22/12	CI
Wockhardt Appoints New CFO	08/22/08	MT
Wockhardt Limited Announces Chief Financial Officer Changes	07/22/07	CI
Wockhardt Limited Reports Earnings Results for the Fourth Quarter and Full Year Ended March 31, 2022	30/22/30	CI
Wockhardt Appoints New CFO	05/22/05	MT
Wockhardt Limited Announces Chief Financial Officer Changes	04/22/04	CI
Wockhardt Ties Up With Serum Institute of India for Vaccine Manufacturing in UK	21/22/21	MT
Wockhardt Gets US Medical Research Agency's Support for Human Phase 1 Trial of Investigational Antibiotic	16/22/16	MT

Wockhardt Limited is a pharmaceutical and biotechnology company. The Company's businesses include manufacture and marketing of pharmaceutical and bio-pharmaceutical formulations, active pharmaceutical ingredients (APIs) and vaccines. It manufactures a range of dosage forms, including sterile injectables and lyophilized products. The Company offers products in therapeutic areas of dermatology, cosmeceuticals, oncology, medical nutrition, osteoarthritis, pain management, nephrology, cough therapy and diabetology. The Companyâs products across India includes Citawok, Citawok Forte, Citawok Plus, CONSEGNA 30/70 U-200 CART, CONSEGNA R U-200 CART, DARBOTIN PFS, DECDAN, DECDAN B, DECDAN B Injection, DECDAN LITE CREAM, Emrok, Emrok O, Erliso, FOSCHEK-S, Gabawok NT, GLARITUS CART, GLARITUS DISPO, Glimaday, INOGLA, Livatira, GLARITUS CART and VAL 450. It has manufacturing and research facilities in India, United States of America and the United Kingdom and a manufacturing facility in Ireland.

Sector

Pharmaceuticals

Calendar

24/05/2024 - Q4 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Generic Pharmaceuticals

	1st Jan change	Capi.
WOCKHARDT LIMITED	+28.04%	1B
SUN PHARMACEUTICAL INDUSTRIES LTD.	+21.63%	44.12B
OTSUKA HOLDINGS CO., LTD.	+22.99%	22.71B
SANDOZ GROUP AG	+18.22%	15.15B
CIPLA LIMITED	+12.66%	13.61B
ZYDUS LIFESCIENCES LIMITED	+60.18%	13.34B
ONO PHARMACEUTICAL CO., LTD.	-8.35%	6.84B
THE MEDICINES COMPANY	-0.05%	6.79B
STADA ARZNEIMITTEL	-8.87%	5.73B
ASPEN PHARMACARE HOLDINGS LIMITED	+12.92%	5.63B

Generic Pharmaceuticals